Take Home Message Antibody-drug conjugates (ADCs) have revolutionized the treatment landscape for metastatic urothelial carcinoma. Encouraging clinical activity of HER2-directed ADCs, including disitamab vedotin, has been observed in early-phase trials. Recent promising results from the RC48-C016 trial raise important questions. We discuss issues that include optimal frontline treatment selection, subsequent-line treatment sequencing, and the generalizability of the findings.
Contextualizing the Development of Anti-HER2 Therapies for Patients with Advanced Urothelial Carcinoma / Maiorano, B.A., Dizman, N., Necchi, A.. - In: EUROPEAN UROLOGY. - ISSN 0302-2838. - 89:6(2026), pp. 479-482. [10.1016/j.eururo.2026.01.027]
Contextualizing the Development of Anti-HER2 Therapies for Patients with Advanced Urothelial Carcinoma
Necchi A.
Ultimo
2026-01-01
Abstract
Take Home Message Antibody-drug conjugates (ADCs) have revolutionized the treatment landscape for metastatic urothelial carcinoma. Encouraging clinical activity of HER2-directed ADCs, including disitamab vedotin, has been observed in early-phase trials. Recent promising results from the RC48-C016 trial raise important questions. We discuss issues that include optimal frontline treatment selection, subsequent-line treatment sequencing, and the generalizability of the findings.| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0302283826000539-main.pdf
solo gestori archivio
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Tutti i diritti riservati
Dimensione
1.07 MB
Formato
Adobe PDF
|
1.07 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
